News & Views | Published:


Predicting late recurrence in ER-positive breast cancer

Identification of factors predicting recurrence of breast cancer is a long-standing goal, ranging from classical clinicopathological factors through to immunohistochemical assays of receptor levels and, more recently, the expression levels of several genes. A new paper now explores novel expression markers, especially for late recurrence of oestrogen receptor-positive breast cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846 (2017).

  2. 2.

    Cuzick, J. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273–4278 (2011).

  3. 3.

    Dowsett, M. et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J. Clin. Oncol. 36, 1941–1948 (2018).

  4. 4.

    Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288–300 (2019).

  5. 5.

    Sestak, I. et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 545–553 (2018).

  6. 6.

    Cheng, L. et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol. Biomarkers Prev. 21, 800–809 (2012).

  7. 7.

    Hamadeh, I. S. et al. Personalizing aromatase inhibitor therapy in patients with breast cancer. Cancer Treat. Rev. 70, 47–55 (2018).

  8. 8.

    Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399–404 (2019).

  9. 9.

    Gellert, P. et al. Breast cancer treatment: a review. JAMA 321, 288–300 (2019).

Download references

Author information

Competing interests

The author declares that he is a consultant for Myriad Genetics, who market the EndoPredict assay (EPclin).

Correspondence to Jack Cuzick.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark